JPMorgan Gives Hims & Hers a $35 Bullish Rating – Full GLP-1 Lineup Just Got Even Stronger
JPMorgan backs Hims & Hers Health as a strong buy, boosted by GLP-1 drugs and big deals with Novo Nordisk and Eli Lilly.
/ 38 items
#HIMS↓
Citi: Amazon’s Cheap GLP-1 Renewals Could Hurt Hims — But Not Replace It
Citi analysts say Amazon One Medical’s new $29 on-demand GLP-1 prescription renewals could pressure Hims & Hers, but they are not a full replacement for the telehealth weight-loss giant.
RFK Jr. Boosts Hims & Hers: FDA to Ease Restrictions on Popular Peptides
Hims & Hers Health jumps as FDA may ease rules on peptides, but experts warn they may be unsafe and lack proper testing.
FDA Tightens Rules on Copycat Ozempic and Wegovy – No More Routine Compounding
FDA limits copycat GLP-1 drugs; pharmacies can only make them during shortages. Original meds like Foundayo now safer & more available.
FDA Moving to Bring Back Popular Injectable Peptides
The FDA is moving to allow compounding pharmacies to produce over a dozen banned injectable peptides. RFK Jr. says he's a big fan and has used them with great results.
Novo & Hims Partner on Ozempic & Wegovy – Lawsuit Dropped
Novo Nordisk and Hims & Hers end their legal battle and team up to offer FDA-approved Ozempic and Wegovy (injections and pills) on the Hims platform. Hims shifts its focus to branded GLP-1s with limited compounded options. Shares surge.